You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLumefantrine
Accession NumberDB06708
TypeSmall Molecule
GroupsApproved
DescriptionLumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas.
Structure
Thumb
Synonyms
(±)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-α-((dibutylamino)methyl)fluorene-4-methanol
2-Dibutylamino-1-[2,7-dichloro-9-(4-chloro-benzylidene)-9H-fluoren-4-yl]-ethanol
2-Dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-9H-fluoren-4-yl}-ethanol
Benflumetol
dl-Benflumelol
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
CoartemNovartis Pharmaceuticals Corporation
SaltsNot Available
Categories
UNIIF38R0JR742
CAS number82186-77-4
WeightAverage: 528.94
Monoisotopic: 527.154947772
Chemical FormulaC30H32Cl3NO
InChI KeyDYLGFOYVTXJFJP-MYYYXRDXSA-N
InChI
InChI=1S/C30H32Cl3NO/c1-3-5-13-34(14-6-4-2)19-29(35)28-18-23(33)17-27-25(15-20-7-9-21(31)10-8-20)26-16-22(32)11-12-24(26)30(27)28/h7-12,15-18,29,35H,3-6,13-14,19H2,1-2H3/b25-15-
IUPAC Name
2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]-9H-fluoren-4-yl]ethan-1-ol
SMILES
CCCCN(CCCC)CC(O)C1=C2C(=CC(Cl)=C1)\C(=C/C1=CC=C(Cl)C=C1)C1=C2C=CC(Cl)=C1
Pharmacology
IndicationLumefantrine and artemether combination therapy is indicated for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum, including malaria acquired in chloroquine-resistant areas. May also be used to treat uncomplicated malaria when the Plasmodium species has not been identified. Indicated for use in adults and children greater than 5 kg.
Structured Indications
PharmacodynamicsLumefantrine is a blood schizonticide active against erythrocytic stages of Plasmodium falciparum. It is thought that administration of lumefantrine with artemether results in cooperate antimalarial clearing effects. Artemether has a rapid onset of action and is rapidly cleared from the body. It is thus thought to provide rapid symptomatic relief by reducing the number of malarial parasites. Lumefantrine has a much longer half life and is believed to clear residual parasites.
Mechanism of actionThe exact mechanism by which lumefantrine exerts its antimalarial effect is unknown. However, available data suggest that lumefantrine inhibits the formation of β-hematin by forming a complex with hemin and inhibits nucleic acid and protein synthesis.
Related Articles
AbsorptionFood increases absorption.
Volume of distributionNot Available
Protein binding99.7% bound
Metabolism

Extensively metabolized in the liver primarily by cytochrome P450 3A4. The major metabolite found in plasma is desbutyl-lumefantrine.

SubstrateEnzymesProduct
Lumefantrine
desbutyl-lumefantrineDetails
Route of eliminationNot Available
Half life~ 4.5 days
ClearanceNot Available
ToxicityCommon side effects of combination artemether/lumefantrine therapy in adults include headache, anorexia, dizziness, and asthenia. Common side effects in children include pyrexia, cough, vomiting, anorexia, and headache. Possible serious adverse effects include QT prolongation, bullous eruption, urticaria, splenomegaly (9%), hepatomegaly (adults, 9%; children, 6%), hypersensitivty reaction, and angioedema.
Affected organisms
  • Plasmodium
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Lumefantrine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe risk or severity of adverse effects can be increased when 5'-Deoxy-5'-Methylthioadenosine is combined with Lumefantrine.Experimental
AcepromazineThe serum concentration of Acepromazine can be increased when it is combined with Lumefantrine.Approved, Vet Approved
AceprometazineThe serum concentration of Aceprometazine can be increased when it is combined with Lumefantrine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Lumefantrine.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Lumefantrine.Approved
AjmalineThe metabolism of Ajmaline can be decreased when combined with Lumefantrine.Approved
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
AlimemazineThe serum concentration of Alimemazine can be increased when it is combined with Lumefantrine.Approved, Vet Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Lumefantrine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Lumefantrine.Approved
AlprenololThe metabolism of Alprenolol can be decreased when combined with Lumefantrine.Approved, Withdrawn
AmantadineAmantadine may increase the QTc-prolonging activities of Lumefantrine.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Lumefantrine.Approved, Withdrawn
AmiodaroneThe serum concentration of Lumefantrine can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Lumefantrine.Approved
AmodiaquineThe risk or severity of adverse effects can be increased when Amodiaquine is combined with Lumefantrine.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Lumefantrine.Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Lumefantrine.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Lumefantrine.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Lumefantrine.Approved
AnagrelideAnagrelide may increase the QTc-prolonging activities of Lumefantrine.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Lumefantrine.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
AprepitantThe serum concentration of Lumefantrine can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Lumefantrine.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Lumefantrine.Approved, Investigational
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Lumefantrine.Approved
ArtemisininThe risk or severity of adverse effects can be increased when Artemisinin is combined with Lumefantrine.Investigational
ArtesunateThe risk or severity of adverse effects can be increased when Artesunate is combined with Lumefantrine.Approved
AsenapineAsenapine may increase the QTc-prolonging activities of Lumefantrine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Lumefantrine.Approved, Withdrawn
AtazanavirThe serum concentration of Lumefantrine can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Lumefantrine.Approved
AtovaquoneThe risk or severity of adverse effects can be increased when Atovaquone is combined with Lumefantrine.Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Lumefantrine.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Lumefantrine.Approved
BedaquilineBedaquiline may increase the QTc-prolonging activities of Lumefantrine.Approved
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Lumefantrine.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Lumefantrine.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Lumefantrine.Approved, Withdrawn
BetaxololThe metabolism of Betaxolol can be decreased when combined with Lumefantrine.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Lumefantrine.Investigational
BexaroteneThe serum concentration of Lumefantrine can be decreased when it is combined with Bexarotene.Approved, Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Lumefantrine.Approved
BL-1020The serum concentration of BL-1020 can be increased when it is combined with Lumefantrine.Investigational
BoceprevirThe serum concentration of Lumefantrine can be increased when it is combined with Boceprevir.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
BosentanThe serum concentration of Lumefantrine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Lumefantrine.Approved
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Lumefantrine.Approved
BufuralolThe metabolism of Bufuralol can be decreased when combined with Lumefantrine.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Lumefantrine.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Lumefantrine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Lumefantrine.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Lumefantrine.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Lumefantrine.Approved, Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Lumefantrine.Approved
CaptoprilThe metabolism of Captopril can be decreased when combined with Lumefantrine.Approved
CarbamazepineThe serum concentration of Lumefantrine can be decreased when it is combined with Carbamazepine.Approved, Investigational
CariprazineThe metabolism of Cariprazine can be decreased when combined with Lumefantrine.Approved
CarteololThe metabolism of Carteolol can be decreased when combined with Lumefantrine.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Lumefantrine.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Lumefantrine.Approved, Vet Approved
CeritinibThe serum concentration of Lumefantrine can be increased when it is combined with Ceritinib.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Lumefantrine.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Lumefantrine.Approved, Illicit
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Lumefantrine.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Lumefantrine.Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Lumefantrine.Approved, Vet Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Lumefantrine.Approved
CilostazolThe metabolism of Cilostazol can be decreased when combined with Lumefantrine.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Lumefantrine.Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
CisaprideCisapride may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the QTc-prolonging activities of Lumefantrine.Approved
ClarithromycinThe serum concentration of Lumefantrine can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Lumefantrine can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Lumefantrine.Approved
ClomipramineClomipramine may increase the QTc-prolonging activities of Lumefantrine.Approved, Vet Approved
ClonidineThe metabolism of Clonidine can be decreased when combined with Lumefantrine.Approved
ClotrimazoleThe metabolism of Lumefantrine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Lumefantrine.Approved
CobicistatThe serum concentration of Lumefantrine can be increased when it is combined with Cobicistat.Approved
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Lumefantrine.Approved, Illicit
ConivaptanThe serum concentration of Lumefantrine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibCrizotinib may increase the QTc-prolonging activities of Lumefantrine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Lumefantrine.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Lumefantrine.Approved, Investigational
CyclosporineThe metabolism of Lumefantrine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Lumefantrine can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Lumefantrine.Approved
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Lumefantrine.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Lumefantrine.Approved, Investigational
DarunavirThe serum concentration of Lumefantrine can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Lumefantrine.Approved
DasatinibThe serum concentration of Lumefantrine can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Lumefantrine.Approved
DeferasiroxThe serum concentration of Lumefantrine can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Lumefantrine.Approved
DelavirdineThe metabolism of Lumefantrine can be decreased when combined with Delavirdine.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Lumefantrine.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Lumefantrine.Approved
DexamethasoneThe serum concentration of Lumefantrine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Lumefantrine.Approved, Illicit, Withdrawn
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Lumefantrine.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Lumefantrine.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Lumefantrine.Approved
DihydroartemisininThe risk or severity of adverse effects can be increased when Dihydroartemisinin is combined with Lumefantrine.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Lumefantrine.Approved, Illicit
DihydroergotamineThe metabolism of Lumefantrine can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Lumefantrine can be decreased when combined with Diltiazem.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Lumefantrine.Approved
DisopyramideDisopyramide may increase the QTc-prolonging activities of Lumefantrine.Approved
DofetilideDofetilide may increase the QTc-prolonging activities of Lumefantrine.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Lumefantrine.Approved
DomperidoneDomperidone may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Lumefantrine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Lumefantrine.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Lumefantrine.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Lumefantrine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Lumefantrine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Lumefantrine.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Doxycycline is combined with Lumefantrine.Approved, Investigational, Vet Approved
DronedaroneDronedarone may increase the QTc-prolonging activities of Lumefantrine.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Lumefantrine.Approved, Vet Approved
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Lumefantrine.Approved
EfavirenzThe serum concentration of Lumefantrine can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Lumefantrine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Lumefantrine.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Lumefantrine.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Lumefantrine.Investigational
EnzalutamideThe serum concentration of Lumefantrine can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Lumefantrine.Approved, Investigational
EribulinEribulin may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Lumefantrine.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Lumefantrine.Approved, Vet Approved
EscitalopramEscitalopram may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Lumefantrine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Lumefantrine.Investigational
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Lumefantrine.Approved, Illicit
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Lumefantrine.Approved, Investigational
EtravirineThe serum concentration of Lumefantrine can be decreased when it is combined with Etravirine.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Lumefantrine.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Lumefantrine.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Lumefantrine.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lumefantrine.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Lumefantrine.Approved, Withdrawn
FluconazoleFluconazole may increase the QTc-prolonging activities of Lumefantrine.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Lumefantrine.Approved
FluoxetineFluoxetine may increase the QTc-prolonging activities of Lumefantrine.Approved, Vet Approved
FlupentixolFlupentixol may increase the QTc-prolonging activities of Lumefantrine.Approved, Withdrawn
FluphenazineThe serum concentration of Fluphenazine can be increased when it is combined with Lumefantrine.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Lumefantrine.Approved
FluvoxamineThe metabolism of Lumefantrine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
FosamprenavirThe metabolism of Lumefantrine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Lumefantrine can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Lumefantrine.Approved
FosphenytoinThe serum concentration of Lumefantrine can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Lumefantrine can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Lumefantrine.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Lumefantrine.Approved
GefitinibThe metabolism of Gefitinib can be decreased when combined with Lumefantrine.Approved, Investigational
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
GoserelinGoserelin may increase the QTc-prolonging activities of Lumefantrine.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
HalofantrineLumefantrine may increase the QTc-prolonging activities of Halofantrine.Approved
HaloperidolHaloperidol may increase the QTc-prolonging activities of Lumefantrine.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Lumefantrine.Approved, Vet Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Lumefantrine.Approved
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Lumefantrine.Approved, Illicit
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Lumefantrine.Approved, Illicit
HydroxychloroquineThe risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Lumefantrine.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Lumefantrine.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Lumefantrine.Approved
IbutilideIbutilide may increase the QTc-prolonging activities of Lumefantrine.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Lumefantrine.Approved
IdelalisibThe serum concentration of Lumefantrine can be increased when it is combined with Idelalisib.Approved
IloperidoneIloperidone may increase the QTc-prolonging activities of Lumefantrine.Approved
ImatinibThe metabolism of Lumefantrine can be decreased when combined with Imatinib.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Lumefantrine.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Lumefantrine.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Lumefantrine.Approved
IndinavirThe serum concentration of Lumefantrine can be increased when it is combined with Indinavir.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Lumefantrine.Approved
IsavuconazoniumThe metabolism of Lumefantrine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneIsoflurane may increase the QTc-prolonging activities of Lumefantrine.Approved, Vet Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Lumefantrine.Approved
ItraconazoleThe serum concentration of Lumefantrine can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Lumefantrine.Approved
IvacaftorThe serum concentration of Lumefantrine can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Lumefantrine.Approved
KetoconazoleThe serum concentration of Lumefantrine can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Lumefantrine.Approved
LapatinibLapatinib may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Lumefantrine.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
LevodopaThe metabolism of Levodopa can be decreased when combined with Lumefantrine.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Lumefantrine.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Lumefantrine.Approved, Vet Approved
LisurideThe metabolism of Lisuride can be decreased when combined with Lumefantrine.Approved
LithiumLithium may increase the QTc-prolonging activities of Lumefantrine.Approved
LomustineThe metabolism of Lomustine can be decreased when combined with Lumefantrine.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Lumefantrine.Approved
LopinavirThe serum concentration of Lumefantrine can be increased when it is combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Lumefantrine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Lumefantrine.Approved
LovastatinThe metabolism of Lumefantrine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Lumefantrine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Lumefantrine can be decreased when it is combined with Lumacaftor.Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Lumefantrine.Approved
MefloquineThe risk or severity of adverse effects can be increased when Mefloquine is combined with Lumefantrine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Lumefantrine.Investigational, Withdrawn
MequitazineThe metabolism of Mequitazine can be decreased when combined with Lumefantrine.Approved
MesoridazineThe serum concentration of Mesoridazine can be increased when it is combined with Lumefantrine.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Lumefantrine.Approved
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Lumefantrine.Approved, Illicit
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Lumefantrine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Lumefantrine.Approved, Vet Approved
Methylene blueThe serum concentration of Methylene blue can be increased when it is combined with Lumefantrine.Investigational
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Lumefantrine.Approved, Investigational
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Lumefantrine.Approved, Illicit, Withdrawn
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Lumefantrine.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Lumefantrine.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Lumefantrine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Lumefantrine.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
MinaprineThe metabolism of Minaprine can be decreased when combined with Lumefantrine.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Lumefantrine.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Lumefantrine.Approved
MitotaneThe serum concentration of Lumefantrine can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Lumefantrine.Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Lumefantrine.Approved
ModafinilThe serum concentration of Lumefantrine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Lumefantrine.Approved
MoricizineThe serum concentration of Moricizine can be increased when it is combined with Lumefantrine.Approved, Withdrawn
MorphineThe metabolism of Morphine can be decreased when combined with Lumefantrine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
NafcillinThe serum concentration of Lumefantrine can be decreased when it is combined with Nafcillin.Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Lumefantrine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Lumefantrine.Approved, Investigational
NefazodoneThe serum concentration of Lumefantrine can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Lumefantrine can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Lumefantrine can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Lumefantrine can be decreased when it is combined with Nevirapine.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Lumefantrine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Lumefantrine.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Lumefantrine.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Lumefantrine.Approved
NilotinibNilotinib may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Lumefantrine.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Lumefantrine.Approved, Vet Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Lumefantrine.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Lumefantrine.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Lumefantrine.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
OlaparibThe metabolism of Lumefantrine can be decreased when combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Lumefantrine.Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Lumefantrine.Approved
OsimertinibThe serum concentration of Lumefantrine can be increased when it is combined with Osimertinib.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Lumefantrine.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Lumefantrine.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Lumefantrine.Approved, Vet Approved
PalbociclibThe serum concentration of Lumefantrine can be increased when it is combined with Palbociclib.Approved
PaliperidonePaliperidone may increase the QTc-prolonging activities of Lumefantrine.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Lumefantrine.Approved, Investigational
PanobinostatPanobinostat may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
ParoxetineParoxetine may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Lumefantrine.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Lumefantrine.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Lumefantrine.Approved
PentobarbitalThe serum concentration of Lumefantrine can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerazineThe serum concentration of Perazine can be increased when it is combined with Lumefantrine.Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Lumefantrine.Approved
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Lumefantrine.Approved
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Lumefantrine.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Lumefantrine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Lumefantrine.Withdrawn
PhenforminThe metabolism of Phenformin can be decreased when combined with Lumefantrine.Approved, Withdrawn
PhenobarbitalThe serum concentration of Lumefantrine can be decreased when it is combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Lumefantrine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozidePimozide may increase the QTc-prolonging activities of Lumefantrine.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Lumefantrine.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Lumefantrine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Lumefantrine.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Lumefantrine.Approved
PosaconazoleThe serum concentration of Lumefantrine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrimaquineThe risk or severity of adverse effects can be increased when Primaquine is combined with Lumefantrine.Approved
PrimidoneThe serum concentration of Lumefantrine can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcainamideProcainamide may increase the QTc-prolonging activities of Lumefantrine.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Lumefantrine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Lumefantrine.Approved, Vet Approved
ProguanilThe risk or severity of adverse effects can be increased when Proguanil is combined with Lumefantrine.Approved
PromazinePromazine may increase the QTc-prolonging activities of Lumefantrine.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Lumefantrine.Approved
PropafenoneThe serum concentration of Lumefantrine can be increased when it is combined with Propafenone.Approved
PropiopromazineThe serum concentration of Propiopromazine can be increased when it is combined with Lumefantrine.Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Lumefantrine.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Lumefantrine.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Lumefantrine.Approved
PyrimethamineThe risk or severity of adverse effects can be increased when Pyrimethamine is combined with Lumefantrine.Approved, Vet Approved
PyronaridineThe risk or severity of adverse effects can be increased when Pyronaridine is combined with Lumefantrine.Investigational
QuetiapineQuetiapine may increase the QTc-prolonging activities of Lumefantrine.Approved
QuinacrineThe risk or severity of adverse effects can be increased when Quinacrine is combined with Lumefantrine.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Lumefantrine.Approved
QuinineThe risk or severity of adverse effects can be increased when Quinine is combined with Lumefantrine.Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Lumefantrine.Experimental
RanitidineThe metabolism of Ranitidine can be decreased when combined with Lumefantrine.Approved
RanolazineRanolazine may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Lumefantrine.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Lumefantrine.Investigational
RifabutinThe serum concentration of Lumefantrine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Lumefantrine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Lumefantrine can be decreased when it is combined with Rifapentine.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Lumefantrine.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
RitonavirThe serum concentration of Lumefantrine can be increased when it is combined with Ritonavir.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Lumefantrine.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Lumefantrine.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Lumefantrine.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Lumefantrine.Approved
SaquinavirThe serum concentration of Lumefantrine can be increased when it is combined with Saquinavir.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Lumefantrine.Approved, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Lumefantrine.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Lumefantrine.Approved, Vet Approved
SildenafilThe metabolism of Lumefantrine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Lumefantrine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Lumefantrine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Lumefantrine.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Lumefantrine.Experimental
SolifenacinSolifenacin may increase the QTc-prolonging activities of Lumefantrine.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
SotalolSotalol may increase the QTc-prolonging activities of Lumefantrine.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Lumefantrine.Experimental
St. John's WortThe serum concentration of Lumefantrine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Lumefantrine can be increased when it is combined with Stiripentol.Approved
SulfadoxineThe risk or severity of adverse effects can be increased when Sulfadoxine is combined with Lumefantrine.Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Lumefantrine.Approved
SulfametopyrazineThe risk or severity of adverse effects can be increased when Sulfametopyrazine is combined with Lumefantrine.Approved, Withdrawn
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Lumefantrine.Approved, Vet Approved
SunitinibSunitinib may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
tafenoquineThe risk or severity of adverse effects can be increased when tafenoquine is combined with Lumefantrine.Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Lumefantrine resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Lumefantrine.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Lumefantrine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Lumefantrine.Investigational, Withdrawn
TelaprevirThe serum concentration of Lumefantrine can be increased when it is combined with Telaprevir.Approved
TelavancinTelavancin may increase the QTc-prolonging activities of Lumefantrine.Approved
TelithromycinThe serum concentration of Lumefantrine can be increased when it is combined with Telithromycin.Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Lumefantrine.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Lumefantrine.Withdrawn
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Lumefantrine.Investigational
TetrabenazineTetrabenazine may increase the QTc-prolonging activities of Lumefantrine.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Lumefantrine.Approved
ThiethylperazineThe serum concentration of Thiethylperazine can be increased when it is combined with Lumefantrine.Withdrawn
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Lumefantrine.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Lumefantrine.Approved
TiclopidineThe metabolism of Lumefantrine can be decreased when combined with Ticlopidine.Approved
TimololThe metabolism of Timolol can be decreased when combined with Lumefantrine.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Lumefantrine.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Lumefantrine.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Lumefantrine.Approved
TocilizumabThe serum concentration of Lumefantrine can be decreased when it is combined with Tocilizumab.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
ToremifeneToremifene may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Lumefantrine.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Lumefantrine.Approved, Investigational
TrazodoneTrazodone may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Lumefantrine.Approved
TriflupromazineThe serum concentration of Triflupromazine can be increased when it is combined with Lumefantrine.Approved, Vet Approved
TrimethoprimThe risk or severity of adverse effects can be increased when Trimethoprim is combined with Lumefantrine.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Lumefantrine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Lumefantrine.Approved, Vet Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Lumefantrine.Approved
VandetanibVandetanib may increase the QTc-prolonging activities of Lumefantrine.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Lumefantrine.Approved
VemurafenibLumefantrine may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Lumefantrine.Approved
VerapamilThe metabolism of Lumefantrine can be decreased when combined with Verapamil.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Lumefantrine.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Lumefantrine.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Lumefantrine.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Lumefantrine.Approved, Investigational
VoriconazoleThe serum concentration of Lumefantrine can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Lumefantrine.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Lumefantrine.Approved, Vet Approved
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Lumefantrine.Approved
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Lumefantrine.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Lumefantrine.Approved
ZuclopenthixolZuclopenthixol may increase the QTc-prolonging activities of Lumefantrine.Approved, Investigational
Food Interactions
  • Grapefruit juice may increase the toxicity of artemether and lumefantrine by inhibiting their metabolism.
  • Take with food as food increases the absorption of lumefantrine and artemether.
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesP01BF01
AHFS Codes
  • 8:30.08
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9363
Caco-2 permeable+0.6319
P-glycoprotein substrateSubstrate0.8389
P-glycoprotein inhibitor IInhibitor0.6854
P-glycoprotein inhibitor IINon-inhibitor0.5475
Renal organic cation transporterInhibitor0.5792
CYP450 2C9 substrateNon-substrate0.7971
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.7076
CYP450 1A2 substrateInhibitor0.6872
CYP450 2C9 inhibitorNon-inhibitor0.7112
CYP450 2D6 inhibitorInhibitor0.7727
CYP450 2C19 inhibitorNon-inhibitor0.6525
CYP450 3A4 inhibitorNon-inhibitor0.6983
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7168
Ames testNon AMES toxic0.6424
CarcinogenicityNon-carcinogens0.7629
BiodegradationNot ready biodegradable0.9924
Rat acute toxicity2.4077 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.7654
hERG inhibition (predictor II)Inhibitor0.776
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility3.09e-05 mg/mLALOGPS
logP8.34ALOGPS
logP9.19ChemAxon
logS-7.2ALOGPS
pKa (Strongest Acidic)14.1ChemAxon
pKa (Strongest Basic)9.78ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area23.47 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity160.81 m3·mol-1ChemAxon
Polarizability60.69 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
ClassificationNot classified

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
Comments
comments powered by Disqus
Drug created on May 15, 2010 19:04 / Updated on November 24, 2016 17:35